Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.

@article{Chevallier2008LongtermDS,
  title={Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.},
  author={Patrice Chevallier and Jacques Delaunay and Pascal Turlure and Arnaud Pigneux and Mathilde Hunault and Richard Garand and Thierry Guillaume and Herv{\'e} Avet-Loiseau and Nathalia Dmytruk and St{\'e}phane Girault and Noel Jean Milpied and Norbert Ifrah and Mohamad Mohty and J. -L. Harousseau},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 32},
  pages={5192-7}
}
PURPOSE To determine the antitumor activity and safety of a combination of gemtuzumab ozogamicin (GO), intermediate-dose cytarabine, and mitoxantrone (MIDAM) in patients with refractory or relapsed CD33(+) acute myeloid leukemia (AML). PATIENTS AND METHODS We treated 62 patients with refractory (n = 18) or relapsed (n = 44) CD33(+) AML. Median age was 55.5 years. Salvage regimen consisted of GO 9 mg/m(2) on day 4, cytarabine 1 g/m(2) every 12 hours on days 1 through 5, and mitoxantrone 12 mg… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

Similar Papers

Loading similar papers…